20th December 2005

Richmond Pharmacology host ground breaking Early Phase Trials Integration seminar at the Royal Society of Medicine

The Early Phase Trials Integration seminar held recently at the Royal Society of Medicine was seen as a huge success by all who attended.

The seminar generated valuable discussions between guest speakers and the Pharmaceutical industry, and explored innovative new ways to maximize the efficiency and speed of Early Phase research.

The seminar focused on the developments around EU Legislations which have re-defined the boundaries of Phase I and opened a new era of opportunity to expedite compounds through the Early Phases.

World leading expert speakers from St George's University London, Mayday University Hospital & NHS trust and the ABPI outlined the new context within which clinical trials are conducted. Presentations on innovative new methodology were reviewed to identify how a CRO like Richmond Pharmacology can add value to pharmacology and patient studies.

Pharmacology and patient studies can now be integrated or work independently of one another. Clinical & therapeutic innovations enable Early Phase research to deliver more dynamic and insightful studies, maximizing the probability of a compound reaching the later Phases.

This new era of Early Phase research demands 3 foundations which were explored during the day:

1. Commercial in- and out-patient facilities
2. Acute NHS environment
3. Therapeutic expertise

Delegate feedback has been positive. Everyone who attended benefited from the highly informative and educational day which was also accredited by the Faculty of Pharmaceutical Medicine (FPM).

View presentations from the seminar

Back to archive